Some of the world’s largest pharmaceutical companies have improved the transparency of their clinical trial data disclosures, according to new analysis from Bioethics International, yet many studies for approved drugs still go unreported. Bioethics International’s second Good Pharma Scorecard, published in the online medical journal BMJ Open, found that companies have made “meaningful progress” on several key metrics since the first scorecard was released in 2015. Companies are doing a better job in complying with legal requirements for reporting clinical trial results, according to the analysis, and making results publicly available for trials conducted in patients. Two companies — Johnson & Johnson and Sanofi — both achieved scores of 100% for clinical trial transparency. In addition, AbbVie, Celgene, Merck and AstraZeneca all scored at or above the industry median of 91%.
展开▼
